What is hemoptysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Hemoptysis

Hemoptysis is the expectoration of blood from the lung alveoli or airways of the lower respiratory tract. 1

Definition and Clinical Significance

  • Hemoptysis must be distinguished from pseudohemoptysis, which originates from nasopharyngeal or gastrointestinal sources rather than the lower respiratory tract. 2

  • The condition represents a clinical symptom with a wide differential diagnosis ranging from benign, self-limited causes to life-threatening emergencies. 3

  • Blood originates primarily from bronchial arteries in most cases of hemoptysis. 2

Classification by Severity

Massive (Life-Threatening) Hemoptysis

  • Massive hemoptysis is defined as hemoptysis placing the patient at high risk for asphyxiation or exsanguination, with volume thresholds varying from >100 mL to >300-400 mL of expectorated blood in 24 hours. 1, 4

  • The rate of bleeding is more important than the absolute volume for determining morbidity and mortality risk. 1, 4

  • Fatal massive hemoptysis results more commonly from asphyxiation rather than exsanguination, as retained blood in the lungs compromises gas exchange. 1

  • Massive hemoptysis carries mortality rates of 50-100%, particularly in patients with underlying lung cancer. 4, 3

Nonmassive Hemoptysis

  • Mild hemoptysis (<30 mL/24 hours) comprises more than 90% of cases and is self-limited with good prognosis. 4, 2

  • Moderate to severe hemoptysis ranges from 30-300 mL in 24 hours. 4

Common Causes (Geographic and Setting-Dependent)

In Outpatient Primary Care Settings

  • Acute respiratory tract infections are the most common cause. 1
  • Chronic obstructive pulmonary disease (COPD) is a frequent etiology. 1
  • Malignancy accounts for a significant proportion of cases. 1
  • Bronchiectasis is commonly identified. 1

In Tertiary Referral Centers (North America/Europe)

  • Bronchiectasis is the leading cause. 1
  • Respiratory infections remain common. 1
  • Lung carcinomas are frequently identified. 1

In Developing Countries

  • Tuberculosis and its sequelae remain the most prevalent cause of hemoptysis globally. 1

Additional Important Causes

  • Sarcoidosis and autoimmune diseases causing pulmonary capillaritis or cavitation. 1
  • Coagulopathies. 1
  • Vascular causes including pulmonary arteriovenous malformations, pulmonary pseudoaneurysms, and pulmonary artery aneurysms. 1
  • Pulmonary embolism is an uncommon cause of hemoptysis. 1

Cryptogenic Hemoptysis

  • Approximately 20% of patients have no identifiable cause despite extensive investigation with CT and bronchoscopy, termed "cryptogenic hemoptysis." 1

  • Some studies report rates as high as 50%, though this is likely inflated due to incomplete diagnostic workup. 1

Critical Clinical Pitfalls

  • Difficulty in clinically quantifying hemoptysis exists due to discordance between expectorated blood and blood retained within the lungs. 1

  • Concomitant hypotension serves as an independent factor in determining massive hemoptysis severity. 1

  • Two or more opacified lung quadrants on frontal chest radiograph correlate with increased risk of mortality. 1, 4

  • The amount of blood loss resulting in death varies based on coexisting cardiopulmonary comorbidities. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Hemoptysis: Evaluation and Management.

American family physician, 2022

Research

Evaluation and management of hemoptysis.

JAAPA : official journal of the American Academy of Physician Assistants, 2025

Guideline

Classification and Management of Hemoptysis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What are the appropriate evaluation and treatment steps for a patient presenting with hemoptysis (coughing blood)?
What is the difference between pulmonary arteries and bronchial arteries, and can Computed Tomography Pulmonary Angiography (CTPA) help identify bronchial arteries in a patient with hemoptysis?
What is the best course of action for a male patient with hemoptysis, recent loose bowel movements, and a negative QuantiFERON test (QFT) result, who is currently stable but requires further evaluation to determine the underlying cause of his symptoms?
What is the appropriate management for a patient presenting with hemoptysis?
What is the appropriate management for a patient presenting with hemoptysis, considering potential underlying conditions and the need for diagnostic workup and treatment?
How does lowering low‑density lipoprotein (LDL) cholesterol stabilize atherosclerotic plaques beyond reducing the lipid core in a typical adult over 40 with moderate‑to‑high cardiovascular risk?
Is apolipoprotein B measurement more sensitive and specific than the traditional lipid panel for assessing atherosclerotic cardiovascular disease risk, especially in patients with type 2 diabetes, and what do current guideline recommendations say?
What is the recommended dose and administration schedule of rasburicase for treating tumor lysis syndrome, including any adjustments for renal impairment or pediatric patients?
What are the components and mechanisms of action of total parenteral nutrition (TPN) for patients unable to receive enteral feeding?
Is cefdinir an appropriate therapy for treating community‑acquired bronchopneumonia in children, particularly in those with a penicillin allergy or who have failed amoxicillin?
What is the appropriate evaluation and management for an otherwise healthy patient presenting with acute pharyngitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.